Arcus Biosciences Inc
RCUS
15.76USD+0.12Â (+0.77%)Market ClosedWatchlist
Market Summary
USD15.76+0.12
Market Closed0.77%
RCUS Alerts
RCUS Stock Price
View Fullscreen
RCUS RSI Chart
RCUS Alerts
RCUS Valuation
RCUS Price/Sales (Trailing)
RCUS Profitability
RCUS Fundamentals
RCUS Revenue
RCUS Earnings
Price Action
Last 7 days
-1.9%
Last 30 days
-1.6%
Last 90 days
-26.3%
Trailing 12 Months
-49.2%
How does RCUS drawdown profile look like?
RCUS Financial Health
RCUS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 119.1M | 121.1M | 119.5M | 0 |
| 2022 | 391.5M | 409.1M | 433.2M | 112.1M |
| 2021 | 85.7M | 93.4M | 38.4M | 383.0M |
| 2020 | 15.0M | 15.0M | 77.8M | 78.0M |
| 2019 | 8.9M | 9.4M | 6.8M | 15.0M |
| 2018 | 2.7M | 3.9M | 8.0M | 8.4M |
| 2017 | 0 | 0 | 0 | 1.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RCUS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Dec 01, 2023 | azoy alexander | sold | -4,215 | 14.95 | -282 | chief accounting officer |
| Sep 22, 2023 | jarrett jennifer | sold | -427,166 | 19.99 | -21,369 | chief operating officer |
| Sep 18, 2023 | nuyten dimitry sa | back to issuer | -75,643 | 20.4 | -3,708 | chief medical officer |
| Sep 18, 2023 | jarrett jennifer | back to issuer | -255,122 | 20.4 | -12,506 | chief operating officer |
| Jul 28, 2023 | jarrett jennifer | sold | -911,250 | 20.25 | -45,000 | chief operating officer |
| Jul 03, 2023 | azoy alexander | sold | -20,777 | 20.41 | -1,018 | chief accounting officer |
| Jun 28, 2023 | gilead sciences, inc. | bought | 19,452,600 | 19.26 | 1,010,000 | - |
| Jun 22, 2023 | jarrett jennifer | sold | -237,795 | 19.12 | -12,437 | chief operating officer |
| Jun 16, 2023 | tang carolyn c. | back to issuer | -55,960 | 19.35 | -2,892 | general counsel |
| Jun 16, 2023 | jaen juan c. | back to issuer | -93,267 | 19.35 | -4,820 | president |
Which funds bought or sold RCUS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 07, 2023 | Hudson Bay Capital Management LP | added | 39.13 | 536,350 | 2,872,000 | 0.01% |
| Dec 06, 2023 | CITIGROUP INC | added | 20.79 | 165,515 | 2,615,840 | -% |
| Dec 04, 2023 | TUCKER ASSET MANAGEMENT LLC | sold off | -100 | -1,016 | - | -% |
| Nov 29, 2023 | Decheng Capital Management III (Cayman), LLC | unchanged | - | -2,052,700 | 15,612,700 | 4.99% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 14.4 | 5,272 | 482,029 | -% |
| Nov 22, 2023 | KBC Group NV | unchanged | - | - | 82,000 | -% |
| Nov 22, 2023 | Public Sector Pension Investment Board | reduced | -29.04 | -707,463 | 1,190,120 | 0.01% |
| Nov 21, 2023 | Walleye Trading LLC | reduced | -54.4 | -924,068 | 623,798 | -% |
| Nov 21, 2023 | COMERICA BANK | added | 2,827 | 441,965 | 441,965 | -% |
| Nov 21, 2023 | Walleye Capital LLC | added | 4.51 | -251,882 | 3,047,800 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Arcus Biosciences Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jul 06, 2023 | gilead sciences, inc. | 35% | 25,586,953 | SC 13D/A | |
| Feb 14, 2023 | biotechnology value fund l p | 1.7% | 1,236,002 | SC 13G/A | |
| Feb 14, 2023 | pfm health sciences, lp | 3.7% | 6 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.04% | 4,373,177 | SC 13G | |
| Jan 26, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
| Oct 17, 2022 | pfm health sciences, lp | 5.5% | 6 | SC 13G | |
| May 09, 2022 | blackrock inc. | 11.1% | 7,967,677 | SC 13G | |
| Mar 14, 2022 | biotechnology value fund l p | 3.0% | 2,156,510 | SC 13G | |
| Feb 14, 2022 | ecor1 capital, llc | 7.9% | 5,523,358 | SC 13G/A |
Recent SEC filings of Arcus Biosciences Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Dec 05, 2023 | 4 | Insider Trading | |
| Nov 07, 2023 | 8-K | Current Report | |
| Nov 07, 2023 | 10-Q | Quarterly Report | |
| Sep 26, 2023 | 4 | Insider Trading | |
| Sep 22, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 15, 2023 | 144 | Notice of Insider Sale Intent |
RCUS Fair Value
Loading...
Peers (Alternatives to Arcus Biosciences Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 6.13% | 411799.31% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 12.59% | -56.51% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 0.38% | -28.56% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 8.71% | -10.95% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 1.18% | -34.97% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 33.62% | 24.68% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 10.65% | 240.88% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -9.53% | 43.40% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 14.00% | -9.85% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.63% | -24.14% | -12.52 | 10.67 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 12.92% | -15.71% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -18.09% | -67.84% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.35% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 385.71% | 119.35% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 40.31% | 4064.72% | -0.5 | - | - | -13.74% |
Arcus Biosciences Inc News
Latest updates
Financials for Arcus Biosciences Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 10.3% | 32,000,000 | 29,000,000 | 25,000,000 | 33,537,000 | 33,581,000 | 27,000,000 | 18,000,000 | 354,617,000 | 9,461,000 | 9,461,000 | 9,461,000 | 9,970,000 | 64,530,000 | 1,750,000 | 1,750,000 | 9,750,000 | 1,750,000 | 1,750,000 | 1,750,000 | 1,562,000 | 4,291,000 |
| Operating Expenses | 0% | 112,000,000 | 112,000,000 | 111,000,000 | 108,059,000 | 102,978,000 | 96,000,000 | 85,000,000 | 73,598,000 | 87,597,000 | 85,597,000 | 82,208,000 | 61,499,000 | 62,978,000 | 47,125,000 | 30,150,000 | 27,277,000 | 24,999,000 | 30,910,000 | 20,523,000 | 15,046,000 | 16,436,000 |
| S&GA Expenses | 7.1% | 30,000,000 | 28,000,000 | 30,000,000 | 27,801,000 | 26,294,000 | 26,000,000 | 24,000,000 | 23,010,000 | 16,343,000 | 16,826,000 | 15,821,000 | 13,383,000 | 11,177,000 | 11,432,000 | 7,008,000 | 6,590,500 | 7,758,000 | 5,911,000 | 4,969,000 | 3,610,000 | 3,577,000 |
| R&D Expenses | -2.4% | 82,000,000 | 84,000,000 | 81,000,000 | 80,258,000 | 76,684,000 | 70,000,000 | 61,000,000 | 50,588,000 | 71,254,000 | 68,771,000 | 66,387,000 | 48,364,000 | 51,801,000 | 35,693,000 | 23,142,000 | 20,686,500 | 17,241,000 | 24,999,000 | 15,554,000 | 11,436,000 | 12,859,000 |
| EBITDA Margin | -3.0% | -2.36 | -2.29 | -2.27 | -2.32 | 0.21 | 0.18 | -0.72 | 0.15 | -7.76 | -3.16 | -1.41 | -1.54 | -1.05 | -5.43 | -5.43 | - | - | - | - | - | - |
| Income Taxes | 100.0% | 2,000,000 | 1,000,000 | 2,000,000 | -2,000 | - | - | 1,000,000 | 2,000,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | 6.8% | -69,000,000 | -74,000,000 | -78,000,000 | -67,270,500 | -64,919,000 | -67,000,000 | -67,000,000 | 281,538,000 | -77,975,000 | -75,970,000 | -72,593,000 | - | - | - | - | - | - | - | - | - | - |
| EBT Margin | -2.8% | -2.41 | -2.35 | -2.33 | -2.37 | 0.19 | 0.17 | -0.73 | 0.14 | -7.85 | -3.20 | -1.44 | -1.58 | -1.09 | -5.65 | -5.65 | - | - | - | - | - | - |
| Net Income | 5.3% | -71,000,000 | -75,000,000 | -80,000,000 | -67,268,500 | -64,919,000 | -67,000,000 | -68,000,000 | 279,538,000 | -77,975,000 | -75,970,000 | -72,593,000 | -51,853,000 | 1,822,000 | -45,074,000 | -27,753,000 | -16,598,000 | -22,352,000 | -28,090,000 | -17,670,000 | -12,295,000 | -10,812,000 |
| Net Income Margin | -3.5% | -2.45 | -2.37 | -2.34 | -2.38 | 0.18 | 0.16 | 0.15 | 0.14 | -7.35 | -2.14 | -1.97 | -1.58 | -1.13 | -7.45 | -6.32 | - | - | - | - | - | - |
| Free Cashflow | -17.7% | -73,000,000 | -62,000,000 | -101,000,000 | -70,119,000 | -82,277,000 | -66,817,000 | 651,213,000 | -70,609,000 | -61,615,000 | -80,068,000 | -69,957,000 | -51,399,000 | 215,194,000 | -24,194,000 | -31,486,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -2.4% | 1,191 | 1,220 | 1,254 | 1,345 | 1,394 | 1,477 | 1,543 | 1,592 | 839 | 899 | 935 | 772 | 811 | 481 | 176 | 203 | 217 | 239 | 259 | 275 | 287 |
| Current Assets | -10.5% | 882 | 986 | 1,015 | 1,067 | 1,101 | 1,227 | 1,264 | 1,262 | 545 | 746 | 842 | 736 | 797 | 472 | 166 | 193 | 200 | 228 | 245 | 259 | 265 |
| Cash Equivalents | -20.0% | 184 | 230 | 238 | 206 | 218 | 273 | 549 | 148 | 179 | 320 | 390 | 173 | 222 | 285 | 67.00 | 58.00 | 79.00 | 76.00 | 68.00 | 71.00 | 75.00 |
| Net PPE | 11.1% | 50.00 | 45.00 | 37.00 | 35.00 | 34.00 | 33.00 | 33.00 | 32.00 | 29.00 | 24.00 | 15.00 | 11.00 | 9.00 | 8.00 | 9.00 | 9.00 | 10.00 | 10.00 | 11.00 | 11.00 | 12.00 |
| Liabilities | - | - | - | - | - | 695 | 729 | 747 | 750 | 297 | 294 | 270 | 270 | 267 | 53.00 | 36.00 | 39.00 | 40.00 | 42.00 | 37.00 | 40.00 | 42.00 |
| Current Liabilities | 11.1% | 200 | 180 | 179 | 193 | 177 | 164 | 161 | 166 | 143 | 130 | 132 | 122 | 163 | 40.00 | 21.00 | 23.00 | 21.00 | 27.00 | 19.00 | 17.00 | 17.00 |
| Shareholder's Equity | -8.1% | 520 | 566 | 600 | 657 | 699 | 747 | 797 | 842 | 543 | 605 | 665 | 502 | 544 | 429 | 141 | 164 | 177 | 197 | 222 | 235 | 245 |
| Retained Earnings | -10.2% | -768 | -697 | -622 | -542 | -474 | -409 | -343 | -275 | -554 | -476 | -400 | -328 | -276 | -278 | -233 | -205 | -188 | -166 | -138 | -122 | -110 |
| Additional Paid-In Capital | - | - | - | - | - | 1,183 | 1,165 | 1,145 | 1,118 | 1,097 | 1,081 | 1,066 | 830 | 821 | 707 | 373 | 369 | 366 | 363 | 360 | 358 | 356 |
| Shares Outstanding | 0.4% | 75.00 | 75.00 | 73.00 | 73.00 | 72.00 | 72.00 | 71.00 | 71.00 | 70.00 | 70.00 | 67.00 | 65.00 | 63.00 | 49.00 | 44.00 | 46.00 | 44.00 | 44.00 | 44.00 | 35.00 | 43.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -10.5% | -63,000 | -57,000 | -98,000 | -69,739 | -81,261 | -65,000 | 654,000 | -61,932 | -53,757 | -73,995 | -66,316 | -50,050 | 216,265 | -23,938 | -31,277 | -9,471 | -27,399 | -19,753 | -16,839 | -7,107 | -11,765 |
| Share Based Compensation | 0% | 18,000 | 18,000 | 19,000 | 16,522 | 16,478 | 15,000 | 17,000 | 14,287 | 14,585 | 13,367 | 12,761 | 8,066 | 6,002 | 4,470 | 3,462 | 2,437 | 2,740 | 2,130 | 1,674 | 1,054 | 1,048 |
| Cashflow From Investing | -57.7% | 11,000 | 26,000 | 129,000 | 46,811 | 23,189 | -215,000 | -268,000 | 18,782 | -88,611 | 3,003 | 62,826 | 136 | -387,119 | -87,073 | 40,056 | -12,104 | 30,364 | 26,673 | 14,279 | 2,511 | -83,337 |
| Cashflow From Financing | -73.9% | 6,000 | 23,000 | 1,000 | 11,195 | 2,805 | 4,000 | 15,000 | 11,331 | 1,318 | 2,231 | 222,120 | 2,002 | 107,518 | 328,870 | 610 | 520 | -41.00 | 649 | -5.00 | 771 | -7.00 |
RCUS Income Statement
2023-09-30Condensed Consolidated Statements of Operations - USD ($) shares in Millions | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 32,000,000 | $ 33,000,000 | $ 86,000,000 | $ 78,000,000 |
| Operating expenses: | ||||
| Research and development (Net of recoveries of $22, $27, $89 and $93 from a related party) | 82,000,000 | 77,000,000 | 247,000,000 | 208,000,000 |
| General and administrative | 30,000,000 | 26,000,000 | 88,000,000 | 76,000,000 |
| Total operating expenses | 112,000,000 | 103,000,000 | 335,000,000 | 284,000,000 |
| Loss from operations | (80,000,000) | (70,000,000) | (249,000,000) | (206,000,000) |
| Non-operating income (expense): | ||||
| Interest and other income, net | 12,000,000 | 5,000,000 | 30,000,000 | 8,000,000 |
| Effective interest on liability for sale of future royalties | (1,000,000) | 0 | (2,000,000) | (1,000,000) |
| Total non-operating income, net | 11,000,000 | 5,000,000 | 28,000,000 | 7,000,000 |
| Loss before income taxes | (69,000,000) | (65,000,000) | (221,000,000) | (199,000,000) |
| Income tax expense | (2,000,000) | 0 | (5,000,000) | (1,000,000) |
| Net loss | $ (71,000,000) | $ (65,000,000) | $ (226,000,000) | $ (200,000,000) |
| Net loss per share, basic (in dollars per share) | $ (0.94) | $ (0.90) | $ (3.07) | $ (2.78) |
| Net loss per share, diluted (in dollars per share) | $ (0.94) | $ (0.90) | $ (3.07) | $ (2.78) |
| Shares used to compute net loss per share, basic (in shares) | 74.6 | 72.2 | 73.6 | 71.8 |
| Shares used to compute net loss per share, diluted (in shares) | 74.6 | 72.2 | 73.6 | 71.8 |
| License and Development Services Revenue | ||||
| Revenues: | ||||
| Total revenues | $ 22,000,000 | $ 23,000,000 | $ 58,000,000 | $ 48,000,000 |
| Other Collaboration Revenue | ||||
| Revenues: | ||||
| Total revenues | $ 10,000,000 | $ 10,000,000 | $ 28,000,000 | $ 30,000,000 |
RCUS Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 184 | $ 206 |
| Marketable securities | 615 | 803 |
| Receivable from collaboration partners ($22 and $39 from a related party) | 52 | 39 |
| Prepaid expenses and other current assets | 31 | 19 |
| Total current assets | 882 | 1,067 |
| Long-term marketable securities | 151 | 129 |
| Property and equipment, net | 50 | 35 |
| Other noncurrent assets ($6 and $2 from a related party) | 108 | 114 |
| Total assets | 1,191 | 1,345 |
| Current liabilities: | ||
| Accounts payable | 17 | 20 |
| Deferred revenue ($96 and $97 to a related party) | 103 | 97 |
| Other current liabilities | 80 | 76 |
| Total current liabilities | 200 | 193 |
| Deferred revenue, noncurrent ($309 and $355 to a related party) | 326 | 355 |
| Other noncurrent liabilities | 145 | 140 |
| Commitments | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share; 10.0 shares authorized; no shares issued and outstanding. | 0 | 0 |
| Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 74.8 shares in 2023 and 72.9 shares in 2022 issued and outstanding | 1,291 | 1,206 |
| Accumulated deficit | (768) | (542) |
| Accumulated other comprehensive loss | (3) | (7) |
| Total stockholders’ equity | 520 | 657 |
| Total liabilities and stockholders’ equity | $ 1,191 | $ 1,345 |
| Â CEO | Dr. Terry J. Rosen Ph.D. |
|---|---|
| Â WEBSITE | www.arcusbio.com |
| Â EMPLOYEES | 500 |